BACKGROUND: Management of psychogenic movement disorders (PMDs) is challenging for neurologists and, to date, there is no consensus about their treatment. Recent studies suggested a possible therapeutic effect of repeated transcranial magnetic stimulation (TMS) in psychogenic paralysis and tremor. OBJECTIVE: To document the clinical impact of TMS in PMDs. METHODS: We blindly video scored symptoms of consecutive patients with PMD who were recorded before and after TMS. TMS was delivered at low frequency (0.25 Hz) over the motor cortex contralateral to symptoms. RESULTS: Twenty-four patients were included. They presented with dystonia, myoclonus, tremor, Parkinsonism or stereotypies. The median duration of symptoms before TMS was 2.8 years (6 months to 30 years). The overall score of 75% of patients improved by >50% and, furthermore, the clinical benefits were sustained upon protracted follow-up (median 19.8 months). There was no correlation between improvement and duration of symptoms before TMS. CONCLUSIONS: TMS is a therapeutic option for PMDs, including chronic PMDs.
BACKGROUND: Management of psychogenic movement disorders (PMDs) is challenging for neurologists and, to date, there is no consensus about their treatment. Recent studies suggested a possible therapeutic effect of repeated transcranial magnetic stimulation (TMS) in psychogenic paralysis and tremor. OBJECTIVE: To document the clinical impact of TMS in PMDs. METHODS: We blindly video scored symptoms of consecutive patients with PMD who were recorded before and after TMS. TMS was delivered at low frequency (0.25 Hz) over the motor cortex contralateral to symptoms. RESULTS: Twenty-four patients were included. They presented with dystonia, myoclonus, tremor, Parkinsonism or stereotypies. The median duration of symptoms before TMS was 2.8 years (6 months to 30 years). The overall score of 75% of patients improved by >50% and, furthermore, the clinical benefits were sustained upon protracted follow-up (median 19.8 months). There was no correlation between improvement and duration of symptoms before TMS. CONCLUSIONS: TMS is a therapeutic option for PMDs, including chronic PMDs.
Authors: Alexander Lehn; Jeannette Gelauff; Ingrid Hoeritzauer; Lea Ludwig; Laura McWhirter; Stevie Williams; Paula Gardiner; Alan Carson; Jon Stone Journal: J Neurol Date: 2015-09-26 Impact factor: 4.849
Authors: Jeannette M Gelauff; Yasmine E M Dreissen; Marina A J Tijssen; Jon Stone Journal: Curr Treat Options Neurol Date: 2014-04 Impact factor: 3.598
Authors: Igor N Petrović; Aleksandra Tomić; Marija Mitković Vončina; Danilo Pešić; Vladimir S Kostić Journal: J Neurol Date: 2017-11-15 Impact factor: 4.849
Authors: Glenn Nielsen; Jon Stone; Audrey Matthews; Melanie Brown; Chris Sparkes; Ross Farmer; Lindsay Masterton; Linsey Duncan; Alisa Winters; Laura Daniell; Carrie Lumsden; Alan Carson; Anthony S David; Mark Edwards Journal: J Neurol Neurosurg Psychiatry Date: 2014-11-28 Impact factor: 10.154
Authors: Carlos Schönfeldt-Lecuona; Jean-Pascal Lefaucheur; Peter Lepping; Joachim Liepert; Bernhard J Connemann; Alexander Sartorius; Dennis A Nowak; Maximilian Gahr Journal: Front Neurosci Date: 2016-03-31 Impact factor: 4.677